214
Views
27
CrossRef citations to date
0
Altmetric
Original Article

Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA

, , , , , , , , , , , & show all
Pages 742-751 | Received 30 Mar 2012, Accepted 17 Jul 2012, Published online: 02 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (9)

Yohannes Shumet, Solomon Ahmed Mohammed, Mesfin Haile Kahissay & Birhanu Demeke. (2021) Catastrophic Health Expenditure among Chronic Patients Attending Dessie Referral Hospital, Northeast Ethiopia. ClinicoEconomics and Outcomes Research 13, pages 99-107.
Read now
Hisashi Yamanaka, Eiichi Tanaka, Ayako Nakajima, Takefumi Furuya, Katsunori Ikari, Atsuo Taniguchi, Eisuke Inoue & Masayoshi Harigai. (2020) A large observational cohort study of rheumatoid arthritis, IORRA: Providing context for today’s treatment options. Modern Rheumatology 30:1, pages 1-6.
Read now
Rosarin Sruamsiri, Jörg Mahlich, Eiichi Tanaka & Hisashi Yamanaka. (2018) Productivity loss of Japanese patients with rheumatoid arthritis – A cross-sectional survey. Modern Rheumatology 28:3, pages 482-489.
Read now
Hayato Yamazaki, Fumio Hirano, Tsutomu Takeuchi, Koichi Amano, Jun Kikuchi, Mari Kihara, Waka Yokoyama, Takahiko Sugihara, Kenji Nagasaka, Hiroyuki Hagiyama, Yoshinori Nonomura, Ryoko Sakai, Michi Tanaka, Ryuji Koike, Toshihiro Nanki, Hitoshi Kohsaka, Nobuyuki Miyasaka & Masayoshi Harigai. (2017) Simplified Disease Activity Index remission at month 6 is an independent predictor of functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis: A multi-center, prospective cohort study in Japan. Modern Rheumatology 27:5, pages 787-794.
Read now
Eiichi Tanaka, Eisuke Inoue, Rei Yamaguchi, Yoko Shimizu, Akiko Kobayashi, Naoki Sugimoto, Daisuke Hoshi, Kumi Shidara, Eri Sato, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi & Hisashi Yamanaka. (2017) Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan. Modern Rheumatology 27:2, pages 227-236.
Read now
Joerg Mahlich & Rosarin Sruamsiri. (2017) Treatment patterns of rheumatoid arthritis in Japanese hospitals and predictors of the initiation of biologic agents. Current Medical Research and Opinion 33:1, pages 101-107.
Read now
Ayako Nakajima, Wako Urano, Eisuke Inoue, Atsuo Taniguchi, Shigeki Momohara & Hisashi Yamanaka. (2015) Incidence of herpes zoster in Japanese patients with rheumatoid arthritis from 2005 to 2010. Modern Rheumatology 25:4, pages 558-561.
Read now
Eiichi Tanaka, Eisuke Inoue, Daisuke Hoshi, Yoko Shimizu, Akiko Kobayashi, Naoki Sugimoto, Kumi Shidara, Eri Sato, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi & Hisashi Yamanaka. (2015) Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Modern Rheumatology 25:4, pages 503-513.
Read now
Kensuke Ochi, Takuji Iwamoto, Asami Saito, Katsunori Ikari, Yoshiaki Toyama, Atsuo Taniguchi, Hisashi Yamanaka & Shigeki Momohara. (2015) Construct validity, reliability, response rate, and association with disease activity of the quick disabilities of the arm, shoulder and hand questionnaire in the assessment of rheumatoid arthritis. Modern Rheumatology 25:2, pages 241-245.
Read now

Articles from other publishers (18)

Kei Ikeda, Yuko Kaneko, Yuki Tsujita, Isao Kawaguchi, Jayeshkumar Patel, Toru Yamazaki, Siran Fang & Yutaka Kawahito. (2023) Healthcare resource utilisation and economic burden of patients with adequate and inadequate responses to biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis in Japan. Modern Rheumatology.
Crossref
Masataka Kuwana, Naoto Tamura, Shinsuke Yasuda, Keishi Fujio, Ayako Shoji, Hiroko Yamaguchi, Katsuhiko Iwasaki, Misako Makishima, Yuichi Kawata, Katsuhisa Yamashita & Ataru Igarashi. (2023) Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data. Modern Rheumatology 33:2, pages 302-311.
Crossref
Hisashi Yamanaka, Mitsumasa Kishimoto, Nobuo Nishijima, Katsuhisa Yamashita, Junnosuke Matsushima, Jacqueline O’Brien, Taylor Blachley, Melissa Eliot, Zachary Margolin, Swapna S Dave & Yoshiya Tanaka. (2023) Socioeconomic impact of treatment with biological disease–modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis. Modern Rheumatology.
Crossref
Tatsuya Atsumi, Eri Asakura, Michio Doi, Ruta Sawant, Isao Kawaguchi, Nobuhito Sasaki & Danny Liew. (2023) Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan. Modern Rheumatology 33:1, pages 54-63.
Crossref
Eiichi Tanaka, Eisuke Inoue, Ayako Shoji, Jonas Nilsson, Christos Papagiannopoulos, Devender Dhanda, Yuri Yoshizawa, Mai Abe, Kumiko Saka, Eri Sugano, Naohiro Sugitani, Moeko Ochiai, Rei Yamaguchi, Katsunori Ikari, Hisashi Yamanaka & Masayoshi Harigai. (2022) Cost-consequence of abatacept as first-line therapy in Japanese rheumatoid arthritis patients using IORRA real-world data. PLOS ONE 17:11, pages e0277566.
Crossref
Hyoungyoung Kim, Soo-Kyung Cho, Jin Wook Kim, Sun-Young Jung, Eun Jin Jang, Sang-Cheol Bae, Dae Hyun Yoo & Yoon-Kyoung Sung. (2020) An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. Seminars in Arthritis and Rheumatism 50:3, pages 526-533.
Crossref
Satoshi Ito, Daisuke Kobayashi, Eriko Hasegawa, Chinatsu Takai, Tetsuya Nemoto, Hyunho Lee, Asami Abe, Hiroshi Otani, Hajime Ishikawa, Akira Murasawa, Ichiei Narita & Kiyoshi Nakazono. (2019) An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients. Internal Medicine 58:4, pages 511-519.
Crossref
Prasan Deep Rath, Der-Yuan Chen, Jieruo Gu, Vivian W. Y. Lee, Nizar Abdulateef Al Ani, Khalid Shirazy & Lyndon Llamado. (2019) Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region. International Journal of Rheumatic Diseases 22:1, pages 9-24.
Crossref
Yoshiya Tanaka, Akiko Mizukami, Akihiro Kobayashi, Chie Ito & Taizo Matsuki. (2018) Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study. International Journal of Rheumatic Diseases 21:8, pages 1609-1618.
Crossref
Hao Hu, Luan Luan, Keqin Yang & Shu‐Chuen Li. (2017) Burden of rheumatoid arthritis from a societal perspective: A prevalence‐based study on cost of this illness for patients in China. International Journal of Rheumatic Diseases 21:8, pages 1572-1580.
Crossref
Hisashi Yamanaka, Eiichi Tanaka, Ayako Nakajima, Takefumi Furuya, Katsunori Ikari & Atsuo Taniguchi. (2017) Achievements from a large cohort study of rheumatoid arthritis関節リウマチの大規模コホート研究とその成果. Nihon Naika Gakkai Zasshi 106:12, pages 2638-2644.
Crossref
Tsutomu Takeuchi, Ryo Nakajima, Shuichi Komatsu, Kiyotaka Yamazaki, Tomohiro Nakamura, Naoki Agata, Ataru Igarashi, Toshiro Tango & Yoshiya Tanaka. (2017) Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study. Advances in Therapy 34:3, pages 686-702.
Crossref
Tatsuhiro Yamamoto, Kotaro Shikano, Toshihiro Nanki & Shinichi Kawai. (2016) Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis. Scientific Reports 6:1.
Crossref
Naonobu Sugiyama, Yutaka Kawahito, Takao Fujii, Tatsuya Atsumi, Tatsunori Murata, Yosuke Morishima & Yuri Fukuma. (2016) Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data. Clinical Therapeutics 38:6, pages 1359-1375.e1.
Crossref
Justice MbizoAnthony OkaforMelanie A. SuttonErica N. BurkhartLeauna M. Stone. (2016) Complementary and Alternative Medicine Use by Normal Weight, Overweight, and Obese Patients with Arthritis or Other Musculoskeletal Diseases. The Journal of Alternative and Complementary Medicine 22:3, pages 227-236.
Crossref
Kensuke Ochi, Takefumi Furuya, Mina Ishibashi, Makiko Watanabe, Katsunori Ikari, Atsuo Taniguchi, Hisashi Yamanaka & Shigeki Momohara. (2015) Risk factors associated with the occurrence of proximal humerus fractures in patients with rheumatoid arthritis: a custom strategy for preventing proximal humerus fractures. Rheumatology International 36:2, pages 213-219.
Crossref
Ayako Nakajima, Eisuke Inoue, Yoko Shimizu, Akiko Kobayashi, Kumi Shidara, Naoki Sugimoto, Yohei Seto, Eiichi Tanaka, Atsuo Taniguchi, Shigeki Momohara & Hisashi Yamanaka. (2014) Presence of comorbidity affects both treatment strategies and outcomes in disease activity, physical function, and quality of life in patients with rheumatoid arthritis. Clinical Rheumatology 34:3, pages 441-449.
Crossref
Chuanhui Xu, Xiuru Wang, Rong Mu, Li Yang, Ye Zhang, Shuling Han, Xiaofeng Li, Yongfu Wang, Guochun Wang, Ping Zhu, Hongtao Jin, Lin Sun, Haiying Chen, Liufu Cui, Zhuoli Zhang, Zhenbin Li, Junfang Li, Fengxiao Zhang, Jinying Lin, Xiaomin Liu, Shaoxian Hu, Xiuyan Yang, Bei Lai, Xingfu Li, Xiaoyuan Wang, Yin Su & Zhanguo Li. (2014) Societal Costs of Rheumatoid Arthritis in China: A Hospital-Based Cross-Sectional Study. Arthritis Care & Research 66:4, pages 523-531.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.